The risks of unproven stem cell treatments – Marketplace

This is Uncomfortable April 18, 2024 Transcript

Note: Marketplace podcasts are meant to be heard, with emphasis, tone and audio elements a transcript cant capture. Transcripts are generated using a combination of automated software and human transcribers, and may contain errors. Please check the corresponding audio before quoting it.

Reema Khrais: Its a beautiful home.

Doris Tyler: Oh, thank you, we love it.

Reema: Im entering a cozy townhouse in Banner Elk, North Carolina. Its tucked away among beautiful mountains with snow on their peaks. Im here to meet Doris Tyler.

Doris: Would you like some water or coffee or anything?

Reema: Im good, thank you so much

Reema: Her home is cozy. Its December. Theres a Christmas tree, wood burning in the fireplace, and family photos everywhere you look

Doris: Im glad you got to come and see the beautiful mountain country we live in up here.

Reema: I know! Its so beautiful

Reema: Right away I feel the type of person Doris is. Full of energy despite her 80 some years. Incredibly warm. We sit down to talk. Her feet dangle from the couch.

Reema: So how would friends and family describe you?

Doris: One of my granddaughters called me Crazy Granny.

Reema: *laugh* Why is that?

Doris: Uh, Im very lively. I love people, I love to meet new people, um, I love hugs.

Reema: How, how would you describe her?

Don: That she loves life.

Reema: Thats Doriss husband, Don. Hes sitting on a recliner across from her. I notice when Doris talks, she becomes his only focus.

Doris: We met singing in the choir and actually started dating on, um, choir tour to California. And, um, I dont know if I should say this but my, he first kissed me in Bernardino, California.

Reema: Aw! Was there, I dont know, like a song early on that you all really connected over?

Doris: Uh, it was When I Fall in Love by Nat King Cole.

MUSIC: When I fall in love it will be forever

Reema: The song says, when I fall in love, it will be forever

Doris: Don said that to me when he kissed me that day in Bernardino, and so thats why.

Reema: Don was enamored with Doriss energetic personality and how unafraid she was to be herself. Like when shed go to baseball games, shed yell so loud her family would joke they could hear her from home. Their romance moved fast.

Doris: We got back from choir tour on April 1st and April 18th we were engaged.

Reema: Wow!

Doris: And we were married August 11th.

Reema: Yall wasted no time!

Doris: And everyone said it wouldnt last! And here it is 61 years.

Reema: Don and Doris lived a happy life together. Both would go on to teach music: Doris taught elementary school and Don taught college. They didnt make a lot of money, but it was enough. Doris was very active, even after retirement. She loved doing things for herself and for her church. And then one day, everything changed.

Doris was driving to a womens meeting at her church. It was starting to get dark. And then it started to rain.

Doris: And cars started coming towards me, and I couldnt, I couldnt see to judge exactly where I was on the road. And, um, so, uh, the further I got, the slower I was driving, trying to, uh, you know, be careful and not run off the road or not hit somebody.

Reema: Her vision was so blurry she could barely see. The road from her home was a little curvy, but Doris had driven this way so many times, it should have been automatic.

Doris: And the more, the more I went, the more, um, upset I got. And I finally just pulled into a parking lot. And I turned around and crept back home.

Reema: When she came inside, Don was surprised to see the state she was in.

Doris: And I was boohooing, boohooing, and Don thought Id had a wreck, because of the way I was. And I told him, when I got in there, I said, I am never, ever driving again! I just was so afraid that I would hurt or kill someone if I, you know, if I caused a wreck, and I just, I couldnt do that. I just couldnt do that. Id rather give up driving than do that.

Reema: Doris went to her eye doctor and learned that she had macular degeneration, which is a common eye disease among older people. It causes the center of your vision to be blurry.

There was good news and bad news: The good news was that she could treat the condition with injections, and that should stop her vision from getting too much worse. With her social security benefits, those injections would cost 200 dollars a month, which seemed more than worth it. The bad news was that her vision would probably never be the same again.

So Doris started getting those injections each month. The idea of a needle in her eye sounded terrifying at first, but she quickly got used to it.

Life went on like that for a while. Don helped Doris as much as he could. Doris could no longer read the small print in her music or her recipes, so Don would type them up for her in bigger fonts.

Don: I mean, I was always on the computer doing something, you know, so I just typed the words for her or whatever that she needed as far as the recipes, didnt seem like that big a deal.

Reema: And then, suddenly, in 2016, the injections stopped working. The doctor told her, theres this other type of injection you can try. But instead of $200 a month, it would cost $2000 a month. Ten times as much. There was just no way they could afford it.

Don and Doris had just about lost hope, when a friend handed them a booklet. The print was small, and Doris couldnt read it, so Don read it aloud to her. It basically described a new technology: stem cells, that could cure all kinds of ailments. The idea was that you could take cells from a healthy part of the body and inject them into a damaged part of the body, and the healthy cells would help the damaged cells heal and regenerate.

Doris learned she could get stem cell injections in her eyes to restore her vision. The procedure would cost $8000 for both eyes.

Reema: At the time, what was $8000 like for you all?

Doris: Well, I, I just said to Don, We cant do it.

Reema: They were retired school teachers who didnt have even 8000 dollars in their savings account. But then, Doriss children had an idea: they insisted on setting up a GoFundMe for her.

Doris: My boys, my sons, they said, Mom, you need to get this, uh, done. You know, this would help you so much.

Reema: Doris had never heard of GoFundMe. She had never heard of stem cells, either. But she did want her vision back.

Im Reema Khrais and youre listening to This is Uncomfortable, a show about life and how money messes with it.

Youve probably heard stories before of people using crowdfunding for their healthcare when insurance wont cover it. Its hard to know how to feel about these stories. Like, on the one hand, its nice to think about people supporting the ones they love; and on the other hand, it paints a bleak picture of our healthcare system. Many Americans cant afford basic medical care.

Doris and her family didnt just have to go outside the traditional insurance system, but the traditional healthcare system too. Stem cells were this new, cutting edge technology. Like, what if they could help Doris drive again or play the piano without squinting?

When Doriss family set up a GoFundMe for her, she didnt expect much to come of it. She didnt realize how beloved she was in the community, how many people, how many former students would be eager to help her restore her vision. But that was just the beginning of the surprises.

Soon after Doriss family set up the GoFundMe, money started pouring in.

Doris: I think within a week maybe two weeks wasnt it, Don? At least a week that we had it. And I was shocked that we had that much.

Reema: Doris sent Don out to buy thank you cards for everyone who donated. They had enough money for the procedure. Doris was relieved.

At that point, they were confident that stem cell treatments were the way to go. Don had been doing a lot of research online about them. Trained doctors were responsible for developing and administering the procedure. Don and Doris had spoken to the doctors on the phone. They said, this is really safe because the injections are coming from your own body.

Don: We put it in your eye, and so, you know, nothing bads gonna happen. I mean, its just part of you going back into you.

Reema: There was a chance it wouldnt work, but that risk seemed more than worth it to Doris. She and Don had selected the stem cell business that was in the pamphlet they got. Their website talks about how they collect data from all over the world, how they have more than 100 clinics in the US alone, and how theyd carefully designed sterile surgical procedures.

Doris: It would either improve my sight or it would stay the same. Uh, which, when you think youre going blind, that sounds pretty good, you know?

Reema: Doris and Don lived in Florida at the time. The closest affiliated clinic was in another state. So they packed up the car and drove.

Doris: Is it 10 hours?

Reema: Thats a long drive.

Don: Uh, no, more like 6 or 7.

Doris: Its between 8 and 10.

View original post here:
The risks of unproven stem cell treatments - Marketplace

Stem-Cell Penis Enlargement: Biohackers Increasing the Size of Their Penis – Men’s Health UK

'You might feel a bee sting' was the warning neurosurgeon Marcella Madera gave Shawn Wells as she made the first of six injections deep into the base of his penis.

The biochemist and entrepreneur soon began to breathe heavily from the extreme discomfort, while Madera continued pumping embryonic stem cells extracted from his legs into his manhood. Is it pain or pressure? Madera asked. Both, was the gritted-teeth response from Wells, who had come to the Restorative Medicine Center in Austin, Texas, for the Adonis Experience, a suite of cutting edge, experimental rejuvenation treatments for men that promise penis enhancement and sexual optimisation.

The desire to enhance the look and feel of ones penis

More recently, doctors have been injecting fat so-called penile fillers from patients stomachs into their penises. There have been apparent successes, but many have been left with wonky, deformed cocks rather than the handsome truncheons they craved. Penile implants and lengthening surgeries, equally, have left some men fulfilled and proud, and others flabbergasted and dismayed. In Sweden, in 2017, a 30-year-old man had a heart attack and died just after having fat cells injected into his penis.

But cutting-edge technological advancements are changing whats possible. Stem-cell injections and shock therapy are becoming the means du jour for men seeking to become more content with their penises, and increasing numbers of men claim they help reverse the inevitable effects of ageing while also improving performance.

It's no wonder people are so excited about it all. Half of all men above 40 are affected by erectile dysfunction, or impotence, and as testosterone levels decline, erections lose strength and orgasms become less intense. Im approaching 50; it's important for it to work just as well as it ever has done, says Wells.

Shawn Wells with Dr Marcella Madera.

A year-and-a-half after his own procedure, Wells says his erections are back to full strength, after having softened with age. Sometimes he hadnt even been able to get an erection or would lose it halfway through sex. That's no longer the case. I gained as much as 20% (in length and strength). It literally looks and feels bigger. Enjoyment levels have increased too. When it's more erect, not only are you giving her more pleasure, youre getting more pleasure too, because the more blood flow there is, the more sensation. And certainly, it lasts longer.

According to Wells account, it appears that he has reversed the symptoms of erectile dysfunction that creep up on men as they grey. He has decreased his penile age, after finally getting stem-cell injections in his dick following almost a decade getting them elsewhere in his body to biohack his biological clock back to age 33. After all, what kind of longevity regimen doesn't also make you 'last longer'?

But Wells isnt the only biohacker taking on penile ageing. Bryan Johnson, the tech entrepreneur and poster boy of the longevity movement, uses a wand-like instrument to shock his penis through acoustic technology in an attempt to reverse his aging dick and get the erections of an 18-year-old.

On a Zoom call at the end of January, Johnson told Mens Health that just the week before he had received Botox injections in his penis after reading that it could be beneficial. It increased blood flow, he says. It increased penile length [and gave me] stronger erections.

Johnson, who says he already had ideal penis health when he embarked on this journey, has previously been lampooned by some for sharing how he straps a small sensor device to his penis several nights a month to measure the strength of his erections and ensure his penile age is decreasing. But night time erections are really important indicators of sexual, physiological and cardiovascular health, he says. When I shared this publicly, several of my friends messaged me to say they think they have none. Theyre all signed up with grind culture, Johnson says, and not prioritising sleep, and therefore their cocks arent working properly.

At his last erection-strength reading, the 46-year-old, who famously spends $2m a year to ward off ageing through various means, was erect for about two hours, 12 minutes on average per night, giving him a penile age of just over 30. To reach the level of a late-teen, he would have to be hard for three-and-a-half hours during sleep.

Unfortunately, the contraption Johnson has been using got a bug preventing fresh data capture over the past two months. A new device is on its way, but for him, the jury has already given its verdict. I perform better sexually than I have in my entire life, he says. In terms of penile health, readiness, and desire. Im probably at peak ability.

Johnson believes the unpleasant extracorporeal sound-wave shocks (in pain terms a 7/10 on the shaft, but 9/10 at the tip, he says) that are said to strengthen the pelvic floor where some of the muscles attached to the base of the penis originate were therefore worth it.

But whats the deeper reason behind the drive to de-age the dick? Johnson and Wells have a history of obesity and depression in common and today theyre hungry to make up for time spent not living their current baller lifestyles and to achieve eternal youth. It took me years to remove that internal demon, Johnson has said. I spent most of my life with PTSD, feeling suicidal, and depressed, says Wells.

Both Wells and Johnson spoke at the longevity and psychedelics conference Wonderland, held by the company Microdose, in Miami, at the end of last year. Another of the attendees, Dave Asprey, author and self-proclaimed father of biohacking, gave a talk on the secrets of brain longevity and declared that he intended to live until at least 180. Id like to have a really active sex life as part of that, he says to Men's Health.

Asprey first received stem-cell injections in his penis in 2015, and has since done the treatment several further times. He also has a shockwave machine at home. Doing those and shockwaves three times, I grew about an inch and a half, he reveals.

Asprey says it was not his goal to change the size of his penis, it was more that he routinely tests new biohacking technologies, but he believes he was the first person to talk publicly about biohacking his penis. It's tough to talk about because bragging about your dick size is the douchiest thing you could do So youd have to ask my girlfriend, thats the kind of results you get from it.

Dave Asprey, the so-called father of biohacking, uses a shockwave machine at home. He says it's enabled him to grow about an inch and a half.

The 50-year-old is content with his role spearheading the wave of penile health consciousness, though he is yet to wear the FirmTech ring at night to measure his erectile health and fitness. But Asprey claims that thousands of men have followed his lead and undergone restorative therapies for erectile dysfunction. I would guess that as a result of my podcast, at least 50,000 guys have gone out and done this, he says. I remember one time I told a group of friends at dinner, guys in their 40s to 60s. All of them went out and got it done. A couple of them came back and were like, Damn, yeah, that worked. One of them had the Peyronie's [disease] where it tilts to one side, and it got straightened out.

Dr Shirin Lakhani, the founder of Elite Aesthetics, started offering penis enhancements with blood plasma back in 2014. Stem-cell treatments are far harder to access in the UK due to medical guidelines, and, it has to be said, the greater propensity of British doctors to act in line with the clinical evidence base. Hundreds of clinics across the US offer a variety of stem-cell therapies, while only about 17 places in the UK provide the so-called P-shots. I'd get a handful of enquiries every week to start with, she recalls. Now we're absolutely inundated.

Dr Shirin Lakhani with a P-shot.

About one-in-five of patients that undergo the procedure dont get any improvements, but some get a 25% increase in girth and 20% increase in length for up to a year on average, and sometimes longer, she says. A great deal of importance has been placed on men by society in being able to have intercourse and perform, she says. I find it incredibly rewarding to be able to help. Giving people back their confidence, improving their lives and their wellbeing. It's just part of being a doctor.

However, many experts are concerned that there is not yet enough robust clinical data to support the growing use of these penile revamp therapies. As of January last year, the published papers on stem-cell therapy for erectile dysfunction included studies performed on fewer than 120 men. In a study on 17 men with perpetually flaccid penises, just under half recovered their erectile function thanks to stem cell injections. Subsequently, they were able to accomplish sexual intercourse. A study with 60 men had similar results, while a meta analysis including 12 human studies found that no major complications were reported in any of the trials.

There is also only preliminary research to prove the efficacy of shockwave therapy, which is a common treatment to dislodge kidney stones. A study in the Scandinavian Journal of Urology had 112 male participants, all of whom had erectile dysfunction and were unable to have sex without Viagra which many men do not respond to and even when it works can cause headaches and nausea. After five weekly low-intensity soundwave shocks along their penises, more than half of the test group were having sex again unaided. That compares to 9% of the placebo group. The treatment was christened as a shocking Viagra alternative.

In its most recent position paper on restorative therapies for erectile dysfunction, the Sexual Medicine Society of North America (SMSNA) acknowledged the treatments represent a promising technology, but warned the current published studies are limited and underpowered. Until larger, higher-quality studies are complete, restorative therapies should be reserved for clinical trials and not offered in routine clinical practice, SMSNA said.

Dr Leigh Turner, a bioethics expert from the University of California, says outfits are persistently making bold marketing claims to attract clients without the clinical evidence to back them up, which is a recipe for patients spending considerable amounts of money for little or no chance of clinical benefits beyond potentially transient placebo effects. Im worried about clinics exploiting the hopes, fears, and anxieties of patients, he says. Its very easy to take advantage of vulnerable individuals who are looking for help.

He warns that US businesses currently marketing stem-cell treatments for erectile dysfunction are often not staffed by urologists or other trained specialists. Rather, many such clinics are staffed by individuals that have no meaningful expertise in erectile dysfunction, urology or mens health.

Still, the desire to enhance the look and feel of ones penis has always been a male obsession. Despite the limited data, anecdotal reports of positive benefits make them a worthwhile risk for many. Thats buttressed by the fact that many athletes, including Tiger Woods and Rafael Nadal, have undergone stem-cell treatments on other parts of their body.

UFC bantamweight champion, Sean OMalley.

UFC bantamweight champion Sean OMalley was at a clinic in Mexico in 2022 to get stem-cell therapy to treat a recurring knee injury when he decided on a whim to get the injections in his penis, too. There's one guy there, and he's like, Yeah I'm getting my dick done, he recalled on his podcast. I think he had erectile dysfunction or something, and I'm like, Well, my wiener works perfectly fine. Is there any cons or is it just pros? The doctors told him it could help with girth, performance, explosive orgasms. So I'm like "Well, it ain't the first time I've had a needle in my wiener, hit me up doc." It was painful and there was serious bruising, but he claims his erect penis is now about four-inches bigger.

It was $5,000 well invested for Wells to ensure he could always get a healthy boner, too. His occasional inability to maintain an erection previously would, naturally, disrupt intimate moments and lead to frustration. It impacts your confidence, he says. I really feel Im living my best and most useful life now.

See the article here:
Stem-Cell Penis Enlargement: Biohackers Increasing the Size of Their Penis - Men's Health UK

Use of intravenous glutathione for skin whitening not FDA approved yet: DOH – PhilStar Life

The Department of Health (DOH) warned about the use of intravenous glutathione for skin whitening as it has not been approved yet by the Food and Drug Administration.

Health secretary Ted Herbosa reminded the public of this in a media forum on Jan. 16.

"Gusto ko sanang i-reiterate... as of now, ang FDA hindi pa po [in-a-approve] ang use ng intravenous glutathione as a skin whitening," he said.

On Jan. 9, a 39-year-old woman died in a hospital in Quezon City hours after undergoing stem cell therapy. The cause of her demise, according to her death certificate, is anaphylactic shock but the antecedent cause is glutathione and stem cell intravenous infusion, as per a Philippine STAR report.

Herbosa also added that the public should check licensed stem cell therapy clinics to avoid risks.

"Babala sa ating mga kababayan para hindi kayo mauwi sa ganitosa morguea sa inyong pagpapaganda, pagpapabata, i-check po sa [DOH] website 'yung listahan ng mga stem cell clinic na lisensyado," he said.

Glutathione is an antioxidant produced in cells made up of amino acids. According to Medical News Today it serves functions such as making DNA, supporting immune functions, regenerating vitamins C and E, and helping the liver and gallbladder. It is also believed to aid skin whitening, anti-aging, and liver and heart disease.

Although it is produced by the body naturally, glutathione can be taken orally, topically, or intravenously.

In the past, the FDA has issued warnings about using intravenous glutathione through Advisory No. 2019-182 as there are no published clinical trials evaluating its use for skin lightening.

"The FDA has not approved any injectable products for skin lightening. Injectable glutathione is approved by FDA Philippines as an adjunct treatment in cisplatin chemotherapy," the statement read.

The institution also listed some risks that come with this including toxic effects on the liver, kidneys, and nervous system.

Originally posted here:
Use of intravenous glutathione for skin whitening not FDA approved yet: DOH - PhilStar Life

Consumers should beware of stem cell treatments for Covid-19 – BioEdge

A recent analysis has identified 38 companies offering so-called stem cell treatments and exosome treatments for preventing as well as treating COVID. These interventions are not supported by convincing safety and efficacy data; they have not been authorised by regulatory bodies such as the Food and Drug Administration (FDA).

The study, led by Professor Leigh Turner, from University of California, Irvine, also found that some of these dubious businesses are claiming to treat long Covid. This is often a debilitating condition that has no proven treatments at present. Some patients with long Covid may have physical symptoms including brain fog, fatigue and headaches that persist for months or possibly years. Desperate patients are extremely vulnerable to misleading claims made by such unscrupulous businesses due to the seriousness of the symptoms they are suffering.

As the human bodys master cells, stem cells have tremendous potential to repair and regenerate cells. However, these therapies have not been approved by regulatory groups. The FDA approved stem cell treatments for only some blood disorders but not for any other medical condition.

In 2021, the early days of the pandemic, Turner published a study regarding 1,480 American businesses promoting unlicensed stem cell-based interventions, some of which even claimed to prevent and treat Covid-19. In the present study, the companies continue to make those same claims while adding claims about long Covid; 36 of the 38 businesses in this analysis stated they had treatments for it. Six companies promoted them as immune boosters, five claimed to treat patients in the acute stage and two businesses stated their products were preventive. As means of advertising their products, some businesses resorted to social media like Facebook, Instagram, Twitter and TikTok. There were also promotional videos on YouTube.

The 38 companies are either operating or facilitating access to 60 clinics. Of the 60 clinics, 24 operate in the US and 22 in Mexico. Other clinics are in Ukraine, Guatemala, Malaysia, Panama, the Philippines, Poland, Spain, Thailand and the United Arab Emirates (UAE). Many of these treatments are costly between US$2,950 and $25,000. Some prices were stated as minimum costs, which suggests that the real expenses might be much more. Health insurance coverage generally does not cover stem cell interventions.

It is critical to have strict oversight as well as enforcement of the existing law. Regulatory bodies, such as the FDA and FTC (Federal Trade Commission) need to play their part enforcing the regulation. The FDAs Center for Biologics Evaluation and Research (CBER) is tasked with regulating cells, tissues and cellular and tissue-based products (HCT/P) which are intended for implantation, transplantation, infusion or transfer into a recipient. The agency has published detailed documents (good tissue practice, donor screening and donor testing requirements), to prevent the introduction, transmission and spread of communicable disease.

The FTC should pursue enforcement action against the clinics based on its jurisdiction over consumer protection issues such misleading and deceptive advertising. This agencys aims include the promotion of competition as well asprotecting and educating consumers. The commission should pursue a legal action when it has reason to believe that the violators are breaking or are about to break the law and it appears that bringing a lawsuit is needed as it is in the public interest. These federal bodies must implement various enforcement steps against these unscrupulous stem cell clinics. The measures should include warning letters and untitled letters and even suing these businesses.

There is at least one case that involves a lawsuit brought against a clinic that promoted stem cell products are treatments for Covid. In State of Washington v. US Stemology LLC and Tami Meraglia, it was alleged that US Stemology violated the states consumer protection legislation by deceptively promoting stem cell treatments of severe conditions, including Covid-19, without scientific basis. These claims were made at the start of the pandemic. A promotion from the company mentioned that a critically ill Covid patient recovered from the treatments. It also claimed a Free Coronavirus Thriving Guide that called stem cell treatment your personalised vaccine against getting sick with Covid-19.It stated, The reason for this is because stem cell therapy treats the lungs first and has long-term anti-inflammatory and immune modulating properties. Ultimately, the parties reached a settlement the company would pay $500,000 to the Attorney Generals Office, whichwill be distributed to the patients.

On a positive note, the National Institutes of Health (NIH) has begun several clinical trials on treating long Covid. Also the FDA has authorised stem cell clinical trials for long Covid. There has been a worrying surge of cases during this holiday period. Thus, patients with Covid, especially those with long Covid, need to shun these unscrupulous clinics peddling dubious treatments. Equally important, the various enforcement agencies need to do their part.

*******

Dr Patrick Foong is a senior law lecturer at Western Sydney University. His research interest lies in bioethics and health law.

Dr Alan W. Leung was a junior faculty at Yale University and Nationwide Childrens Hospital, and led iPSC product development at CRISPR therapeutics and Elevatebio. He is currently a freelance life science consultant and writer. His research interest lies in human embryonic stem cell therapy and preclinical applications.

Dr Patrick Foong is a senior law lecturer at Western Sydney University. His research interest lies in bioethics and health law.

Read the original here:
Consumers should beware of stem cell treatments for Covid-19 - BioEdge

Review shows benefits of regenerative medicine for joint issues in … – Horsetalk

Horsetalk.co.nz

Several regenerative therapies represent a promising and highly effective approach for the treatment of joint problems in horses, according to the authors of a just-published review.

Andrea Prez Fraile and her colleagues, writing in the journal Veterinary Sciences, said musculoskeletal injuries in horses are important, mainly due to their economic and sporting implications.

The tissues most affected by such injuries include tendons, ligaments and cartilage, all of which have a restricted ability to self-heal.

This is where regenerative therapies arise, which involve the use of living cells and non-cell therapies to treat various diseases, injuries, and medical conditions and to restore the affected tissue to its native state, both structurally and functionally.

The researchers performed a systematic review, searching the PubMed and Web of Science databases for articles on regenerative medicine for equine musculoskeletal injuries.

Their review covered 17 experimental clinical studies categorized by the therapeutic approach used: platelet-rich plasma, conditioned autologous serum, mesenchymal stem cells, and the secretome.

Overall, they found regenerative medicine based on cell therapy to be highly effective in osteoarticular injuries in horses due to the regenerative and anti-inflammatory properties of these therapies, making them a promising alternative for the treatment of musculoskeletal injuries in horses.

The most commonly used cellular therapies in regenerative medicine in equine clinics today include mesenchymal stem cell therapy, platelet-rich plasma, autologous conditioned serum, and other therapies in the developmental phase such as the secretome.

The problems most treated with regenerative medicine, obtaining satisfactory results, include bone tissue injuries, ligament and tendon injuries, osteoarthritis, and degenerative joint diseases.

Regenerative medicine is considered a treatment option when conventional therapies have not yielded satisfactory results or when a more advanced therapeutic option focused on tissue regeneration is sought, they said.

It should be pointed out that these results obtained in the treatment of injured horses, in addition to their inherent economic implications, have an enormous interest in translational medicine to human beings in this context.

These kinds of therapies seem to be preferable to other potential therapies, i.e., replacement surgery, with its inherent decrease in the fitness of the patient, and avoid the risks and ethical concerns of other potential treatments like gene therapies.

The authors said experimental studies in horses have shown promising results in terms of tissue repair and regeneration largely due to the potential benefits of mesenchymal stem cells.

However, further research in this field is considered necessary to support its effectiveness and establish clear guidelines for its use in clinical practice.

The lack of controlled clinical trials limits the strength of this evidence, they said.

Moreover, the importance of conducting medium- and long-term evaluations to determine the durability and sustained efficacy of these therapies is highlighted.

This, they said, is particularly relevant in cases of chronic or degenerative injuries, where long-term evaluation is essential to understand the real impact of the treatment.

The lack of factual conclusions based on long-term analysis, coupled with high economic costs compared to other regenerative medicine techniques, implies the need to perform a costbenefit analysis to ensure and justify the use of this type of therapy in clinical practice.

The review team comprised Prez Fraile, Elsa Gonzlez-Cubero, Susana Martnez-Flrez, Elas Olivera, and Vega Villar-Surez, all with the University of Len in Spain.

Prez Fraile, A.; Gonzlez-Cubero, E.; Martnez-Flrez, S.; Olivera, E.R.; Villar-Surez, V. Regenerative Medicine Applied to Musculoskeletal Diseases in Equines: A Systematic Review. Vet. Sci. 2023, 10, 666. https://doi.org/10.3390/vetsci10120666

The review, published under a Creative Commons License, can be read here.

Read more here:
Review shows benefits of regenerative medicine for joint issues in ... - Horsetalk

Dynamic Stem Cell Therapy Unlocks the Power to Heal and … – Las Vegas Review-Journal

No matter your age, physical activity or stage in life, an injury or medical condition will profoundly affect your way of life. There can be plenty of fear and worry that goes along with these sorts of thing, still you want to feel good. Dynamic Stem Cell Therapy is a Nevada Regenerative Medicine clinic that will help you find the right solution for your unique situation and return you to living the life you love.

Stem cells are the bodys natural healers. Stem cell therapy is a way to boost thebodys abilityto heal itself by giving the body healthier cells. As we age, along with over-usage of our joints, this natural ability diminishes, and we get hurt more often and frequently. Stem cell therapy is a way to boost that ability by giving the body healthier cells.

These cells can be harvested from our own bodies or after-birth material. These sources lay dormant in fat tissue and bone marrow and also can be obtained from living birth tissue, such as the umbilical cord or placenta after a live healthy birth of a baby. Specific stem cells go toward inflammation and injury. They get to the root cause, and then they promote the recruitment of more specialized stem cells to come to the area to mitigate, or even resolve the patients problem completely.

Stem cells are the building blocks of the human body, says Dynamic Stem Cell Therapy Co-founder and CEO Blake Youmans.

Stem cell therapy is a revolutionary alternative treatment with the potential to help the body heal itself at the root cause. Stem cells, as the building blocks of life, have the ability to develop into many types of cells to aid in treating injuries and diseases. They can even help keep you healthy longer and prevent diseases. For example, some of the many conditions stem cell therapy can be used to treat include spinal cord injuries, all joint strains and pain, arthritis, osteoarthritis and some autoimmune diseases.

Another benefit is that surgery is potentially not needed with stem cell therapy. Treatments are minimally invasive and usually involve an injection into the affected area. As a result, there is little downtime. With this treatment, a person can return to a regular routine and enjoy activities that may have been stopped due to the injury or illness.

Stem cell therapy is a natural treatment utilizing the bodys healing mechanisms. Stem cells can be harvested from the patients body or other safe and tested sources including umbilical cord tissue. The therapy is safe since there is no risk of allergic reaction or rejection, making it a practical option.

Treatments can potentially reverse the trauma that has been sustained, giving their patients a better quality of life. The world-class clinic offers the best techniques, procedures and equipment to provide its patients with the finest treatments and outcomes. Since treatments are tailored to each individual need, these procedures are accessed bi-annually for improvements and are focused on providing the best treatments currently available. An integral part of the business includes attending conferences, continuing education about advancements in the field and recruiting top team members.

We have been here in Las Vegas for 10 years with over 150 reviews with 4.8 stars. We built the business through word-of-mouth and our reputation. We care deeply about the patient outcome, says Youmans.

Another concern for Dynamic Stem Cell Therapy is that people mistakenly believe they must go to another country, such as Mexico, for these treatments.

You dont have to leave the state or even the country to receive this ground-breaking, top-of-the-line treatment and therapy, says Youmans. People will listen to podcasts, and popular podcasters will discuss clinics in Mexico, Columbia and Panama. However, there was a time when they would talk about stem cell therapy here in Las Vegas, and we are still here, providing the best care possible.

Southern Nevada is set up to become a medical destination with a foundation already in place to accommodate national and international visitors. Along with world-class stem cell treatment, visitors and their families will have the ability to also experience healthy opportunities in Las Vegas.

Youmans has followed his passion for developing a business to help people become well, with a preventative approach involving regenerative medicine. Youmans has managed medical establishments for 10 years after receiving his Bachelor of Science in biology from the College of Charleston, South Carolina. He relocated to Nevada in 2003, becoming a nationally registered paramedic, and witnessed patients getting emergent care needed for problems that could have been prevented. His desire to help others motivated him to develop Dynamic Stem Cell Therapy.

This revolutionary alternative treatment option, offered by Dynamic Stem Cell Therapy, can provide procedures to aid in healing injuries and diseases. Minimal invasiveness, natural healing properties, anti-aging benefits and no risk of rejection or allergic reaction create viable treatment options. More importantly, the clinic is located in Southern Nevada and is easily accessible nationally and globally.

Dynamic Stem Cell Therapy is located at 2551 N. Green Valley Parkway, Henderson, with easy access in Southern Nevada. For more information, call (702) 547-6565 or visit stemcellpowernow.com.

Members of the editorial and news staff of the Las Vegas Review-Journal were not involved in the creation of this content.

Continued here:
Dynamic Stem Cell Therapy Unlocks the Power to Heal and ... - Las Vegas Review-Journal

Stem Cell Therapy Market Research Insights with Upcoming Trends, Size, Share, Segmentation, Business Opportuni – openPR

The Stem Cell Therapy Market size is expected to grow from US$ 2,278.49 million in 2022 to US$ 6,206.89 million by 2028. The market is estimated to register a CAGR of 18.2% from 2022 to 2028.

Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under a controlled environment in the body or a clinical laboratory, these cells divide to form more cells, called daughter cells. With the advent of modern health science, these cells have been demonstrated to play a major role in understanding the occurrence of diseases, the generation of advanced regenerative medicines, and the discovery of other drugs. Stem cells are formed in embryos, bone marrow, body fats, and umbilical cord blood, among others.

Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00000960?utm_source=OpenPr&utm_medium=10640

The List of Companies - 1.MEDIPOST2.RichSource3.BioTime, Inc.4.Mesoblast Limited5.Holostem Terapie Avanzate Srl6.U.S. Stem Cell, Inc.7.TiGenix NV8.AlloSource9.NuVasive Inc10.JCR Pharmaceuticals Co. Ltd.

The US is investing massive resources in its healthcare sector for accelerating research and development activities in stem cell technologies. These activities are projected to drive organic developments such as product launches, product approvals, and new product innovations. Financial aid from investors, government authorities, and significant players is, thus, likely to favor the stem cell therapy market growth in the US. In July 2019, Century Therapeutics raised US$ 250 million through a financing round to develop induced pluripotent stem cells (iPSC), which will be utilized in an allogeneic cell therapy platform.

Moreover, in December 2019, NIH launched the US's first clinical study of patient-derived stem cell therapy for the treatment of the retina. Such studies, combined with developments in regenerative medicine, are expected to drive the acceptance and adoption of stem cell therapy in the US, which, in turn, will drive the market by 2027.

For instance, in May 2019, SpinalCyte, LLC, a clinical-stage regenerative medicine company, announced the launch of a new comprehensive platform to raise awareness of the potential benefits served by fibroblasts and their promising applications in regenerative medicine technology.

Get full Report Description, TOC, Table of Figure, Chart, etc. @: https://www.premiummarketinsights.com/reports-tip/stem-cell-therapy-market

The stem cell therapy market in Canada is expected to grow in the future owing to the development of the healthcare sector and rapidly increasing investments in stem cell therapy technology. On the other hand, in Mexico, increasing awareness of the benefits offered by stem cell therapy would benefit the stem cell therapy market.

In 2020, Australia, Japan, Korea, and New Zealand took better measures than other Asia Pacific countries to flatten the curve of SARS-CoV-2 infection. They developed effective testing, tracing, and isolation systems to ensure that people comply with social distancing and similar key guidelines. Other countries, including Vietnam and Thailand, demonstrated the value of a proactive response to contain the virus and limit deaths. However, the onset of the COVID-19 crisis severely affected cancer, heart disease, diabetes, HIV, tuberculosis, and malaria prevention and treatment services in Asia Pacific. The number of COVID-19 cases in India has dropped significantly compared to trends recorded in 2020 and 2021. The repercussions of the pandemic, including supply chain disruptions owing to extended factory shutdowns and production delays, persisted for a short period. However, as the demand exceeded supply, the country experienced a hike in commodity prices.

In a new research methodology for developing a treatment for COVID-19, stem cell therapy and stem-cell-derived organoid models have received high attention. Additionally, clinical studies reveal that various organoids derived from stem cells act as an ideal model to explore the possibility and mechanism of SARS-CoV-2 infecting multiple organs, and the outcomes can better research for clinical treatment. Moreover, stem cell therapy was made available for severe COVID-19 patients and for people recovered from severe complications to facilitate the repair of damaged lungs.

Buy this research report at @: https://www.premiummarketinsights.com/buy/TIP00000960?utm_source=OpenPr&utm_medium=10640

The COVID-19 pandemic disrupted people's lives and business operations worldwide. The COVID-19 pandemic had a positive impact on the stem cell therapy market. The application of stem cells in the treatment of COVID-19 infection has gathered the attention of medical researchers, resulting in a higher number of clinical trials. Regenerative medicine based on cellular therapies may be developed as a treatment option for patients, lowering infection rates and mortality. Research institutes and companies are collaborating to develop novel treatment options for the disease. For instance, in April 2020, Infectious Disease Research Institute and Celularity announced that the US FDA had approved a clinical trial application to develop cell-based therapy for COVID-19. Thus, researchers are increasingly attempting to develop stem cell therapies targeting COVID-19. In January 2020, researchers from the University of Miami administered two stem cell infusions to COVID-19 patients suffering from lung damage. The results concluded that there were no significant side effects, and the therapy was reliable. Thus, increasing demand for regenerative medicines has had a positive effect on the stem cell therapy market during the COVID-19 pandemic.

Application-Based InsightsBased on application, the stem cell therapy market is divided into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications. The drug discovery and development segment held the largest share of the market in 2021 and is expected to register the highest CAGR during the forecast period.

End User-Based InsightsBased on end user, the stem cell therapy market is segmented into academic & research institutes and hospitals & clinics. The academic & research institutes segment held a larger share of the market in 2021, and the same segment is expected to register a higher CAGR during the forecast period (2022-2028).A few of the major primary and secondary sources referred to while preparing the report on the stem cell therapy market are the World Health Organization (WHO), the US Census Bureau, and the US National Library of Medicine.

TABLE OF CONTENTS1. Introduction1.1 Scope of the Study1.2 Research Report Guidance1.3 Market Segmentation1.3.1 - By Type1.3.2 - By Treatment1.3.3 - By Application1.3.4 - By End User1.3.5 - By Geography2. - Key Takeaways3. Research Methodology3.1 Coverage3.2 Secondary Research3.3 Primary Research4. - Market Landscape4.1 Overview4.2 PEST Analysis4.2.1 North America PEST Analysis4.2.2 Europe - PEST Analysis4.2.3 Asia Pacific - PEST Analysis4.2.4 South and Central America - PEST Analysis4.2.5 Middle East and Africa PEST Analysis4.3 Experts Opinion5. - Key Market DynamicsContinued

Other Reports:

Industrial Hard Margarine Market Forecast to 2028 - https://www.marketwatch.com/press-release/industrial-hard-margarine-market-key-players-applications-outlook-swot-analysis-and-forecasts-by-2028-2023-03-31?mod=search_headline

Biosimilars Market Forecast to 2028 - https://www.marketwatch.com/press-release/biosimilars-market-business-growth-size-and-comprehensive-research-study-forecast-to-2028-2023-03-31?mod=search_headline

Luxury Yacht Market Forecast to 2028 - https://www.marketwatch.com/press-release/luxury-yacht-market-size-share-regional-demand-and-geographical-forecast-till-2028-2023-03-31?mod=search_headline

Coagulation Analyzer Market Forecast to 2028 - https://www.marketwatch.com/press-release/coagulation-analyzer-market-competition-to-heat-up-with-launch-innovative-technologies-reported-worldwide-2023-03-31?mod=search_headline

Contact Us:If you have any queries about this report or if you would like further information, please Contact Person: Sameer JoshiPhone: +1-646-491-9876Email: sales@premiummarketinsights.com

About Us:Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

This release was published on openPR.

See the rest here:
Stem Cell Therapy Market Research Insights with Upcoming Trends, Size, Share, Segmentation, Business Opportuni - openPR

Cord Blood Bank Market to Witness Massive Growth by Stemcyte … – Digital Journal

PRESS RELEASE

Published April 4, 2023

The Latest Released Cord Blood Bank market study has evaluated the future growth potential of Cord Blood Bank market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision-makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, and emerging trends along with essential drivers, challenges, opportunities, and restraints in the Cord Blood Bank market. The study includes market share analysis and profiles of players such as CBR systems, Inc. (United States), Cordlife (Singapore), Cryo-cell (United States), Cryo-Save AG (Europe), LifeCell (India), Stemcyte (India), ViaCord,Inc. (United States), Virgin Health Bank (U.K), Neostem, Inc.(United States)

If you are a Cord Blood Bank manufacturer and would like to check or understand the policy and regulatory proposals, designing clear explanations of the stakes, potential winners and losers, and options for improvement then this article will help you understand the pattern with Impacting Trends. Click To get SAMPLE PDF (Including Full TOC, Table & Figures) https://www.htfmarketintelligence.com/sample-report/global-cord-blood-bank-market

According to HTF Market Intelligence, the Global Cord Blood Bank market to witness a CAGR of 11% during forecast period of 2023-2029. The market is segmented by Global Cord Blood Bank Market Breakdown by Application (Cell Based Therapies, Hematopoietic Stem Cell Transplantation, Immunotherapy, Tissue Engineering, Blood Disorders, Metabolic Disorders, Osteoporosis, Cancer and Diabetes Treatment) by Type (Public Cord Blood Banks, Private Cord Blood Banks, Hybrid Cord Blood Banks) by End User (Hospitals, Research Institutes, Specialty Clinics) by Service (Stem Cell Storage Services, Genetic & Genomic Testing Services, Reproductive Health Services) and by Geography (North America, South America, Europe, Asia Pacific, MEA)

Definition:

Rapid advancement in cord blood storage and processing technologies aid in the rapid expansion of the Cord Blood Bank (CBB) market. Also, With the increased spending capacity of the people and the demand for advanced healthcare facilities including disease prevention and treatment, these factors are boosting the global cord blood bank market. Cord blood banks are the location where blood can be stored from the umbilical cord for future use. These are involved in medical data keeping and storage which also charge annual fees for storage and maintenance. The increasing application of cord blood and stem cells in genetic disease treatment is primarily driving the global cord blood banking services market.

Market Trends:

Market Drivers:

Market Opportunities:

Revenue and Sales Estimation - Historical Revenue and sales volume are presented and further data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast numbers for key regions covered in the report along with classified and well-recognized Types and end-use industry.

SWOT Analysis on Cord Blood Bank PlayersIn addition to Market Share analysis of players, in-depth profiling, product/service, and business overview, the study also concentrates on BCG matrix, heat map analysis, FPNV positioning along with SWOT analysis to better correlate market competitiveness.

Demand from top-notch companies and government agencies is expected to rise as they seek more information on the latest scenario. Check the Demand Determinants section for more information.

Regulation Analysis- Local System and Other Regulation: Regional variations in Laws for the use of Cord Blood Bank- Regulation and its Implications- Other Compliances

Have Any Query? Ask Our Expert @: https://www.htfmarketintelligence.com/enquiry-before-buy/global-cord-blood-bank-market

FIVE FORCES & PESTLE ANALYSIS:

In order to better understand market conditions five forces analysis is conducted that includes the Bargaining power of buyers, Bargaining power of suppliers, Threat of new entrants, Threat of substitutes, and Threat of rivalry.

- Political (Political policy and stability as well as trade, fiscal, and taxation policies)- Economical (Interest rates, employment or unemployment rates, raw material costs, and foreign exchange rates)- Social (Changing family demographics, education levels, cultural trends, attitude changes, and changes in lifestyles)- Technological (Changes in digital or mobile technology, automation, research, and development)- Legal (Employment legislation, consumer law, health, and safety, international as well as trade regulation and restrictions)- Environmental (Climate, recycling procedures, carbon footprint, waste disposal, and sustainability)

Book Latest Edition of Cord Blood Bank Market Study @ https://www.htfmarketintelligence.com/buy-now?format=3&report=1354

Heat map Analysis, 3-Year Financial and Detailed Company Profiles of Key & Emerging Players: CBR systems, Inc. (United States), Cordlife (Singapore), Cryo-cell (United States), Cryo-Save AG (Europe), LifeCell (India), Stemcyte (India), ViaCord,Inc. (United States), Virgin Health Bank (U.K), Neostem, Inc.(United States)

Geographically, the following regions together with the listed national/local markets are fully investigated:- APAC (Japan, China, South Korea, Australia, India, and the Rest of APAC; the Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)- Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)- North America (U.S., Canada, and Mexico)- South America (Brazil, Chile, Argentina, Rest of South America)- MEA (Saudi Arabia, UAE, South Africa)

Some Extracts from Cord Blood Bank Market Study Table of Content

Cord Blood Bank Market Size (Sales) Market Share by Type (Product Category) [] in 2023Cord Blood Bank Market by Application/End Users []Global Cord Blood Bank Sales and Growth Rate (2019-2029)Cord Blood Bank Competition by Players/Suppliers, Region, Type, and ApplicationCord Blood Bank (Volume, Value, and Sales Price) table defined for each geographic region defined.Supply Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis........and view more in complete table of Contents

Check it Out Complete Details os Report @ https://www.htfmarketintelligence.com/report/global-cord-blood-bank-market

Thanks for reading this article; you can also get individual chapter-wise sections or region-wise reports like Balkan, China-based, North America, Europe, or Southeast Asia.

Contact Us :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedPhone: +1 434 322 0091[emailprotected]

COMTEX_428325118/2808/2023-04-04T07:37:51

Read more here:
Cord Blood Bank Market to Witness Massive Growth by Stemcyte ... - Digital Journal

Hair Transplant Global Market Report 2023: Increasing use of Follicular Unit Extraction Drives Growth – Yahoo Finance

Company Logo

Global Hair Transplant Market

Global Hair Transplant Market

Dublin, March 02, 2023 (GLOBE NEWSWIRE) -- The "Hair Transplant Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Global Hair Transplant Market is expected to reach US$ 53.17 Billion by 2028, according to the publisher. The hair transplant industry is a developing and a attractive sector, driven by rising demand for cosmetic surgeries to enhance looks and self-esteem. Advances in surgical procedures and instruments, as well as increased public knowledge of the process, have all contributed to the industry's expansion in recent years.

For example, the International Society of Hair Restoration Surgery (ISHRS) predicts that 2,221,191 hair restoration treatments would be conducted worldwide in 2021, with hair restoration procedures increasing by 7% globally between 2019 and 2021.

Hair Transplant Growth Trends appears to grow with a double-digit CAGR of 23.84% during 2022-2028

The increasing frequency of chronic diseases like cancer, hyperthyroidism, and hypothyroidism causes hair loss, which drives market expansion. Increased usage of chemotherapies, which causes hair loss and increases demand for hair transplant surgery. The market is growing because to an increase in the number of product approvals and product launches for hair transplantation procedures.

However, the sector confronts a number of obstacles, including a lack of standardization and regulation, as well as the possibility of substandard outcomes from unskilled or unlicensed practitioners. As a result, patients considering hair transplant surgeries should do their homework and select a trained and recognized surgeon to achieve the best potential results. For the year 2022, Hair Restoration Market World over was worth US$ 17.75 Billion.

Increasing Surgeries at Hospitals and Clinics to Aid Market Share

Hair transplants can be done in a variety of settings, including hospitals, clinics, surgical centres, and other facilities. Clinics that perform hair transplant surgeries may also provide additional hair loss therapies such as topical and oral medicines, laser therapy, and scalp micropigmentation. Patients must conduct research and select a reputed and competent clinic for their hair transplant process. Look for clinics that have a trained medical staff, employ established treatments, and have a track record of favourable results.

Overall, the hair transplant market in Clinics is expanding, fueled by rising demand for hair restoration surgeries and technological developments. For example, HHC (Hermest Hair Clinic) established a cost-effective and innovative follicular unit extraction (FUE) technique service for hair transplants in Turkey in April 2022. Such innovations are expected to drive market expansion over the study period.

Hair transplant treatments are often conducted in hospitals as part of a bigger medical centre that provides a full range of medical services and resources. Emergency services are frequently offered in hospitals, which can give an additional degree of protection for individuals having hair transplant surgeries. The hospitals segment is predicted to grow significantly during the hair transplant market projection period, owing to the availability of various hair transplant procedures and an increase in government investment to strengthen the healthcare sector.

The Increasing use of Follicular Unit Extraction (FUE) will Drive Market Growth

To restore hair in bald areas, several hair transplantation techniques such as follicular unit transplantation (FUT) and follicular unit extraction (FUE) are undertaken. Hair transplantation is most typically used to treat male pattern baldness, but it can also be used to treat female hair loss and balding. FUE is a popular hair restoration method because it has numerous advantages over traditional hair transplant procedures, such as less invasiveness, more natural-looking outcomes, a quicker recovery period, and a high degree of customisation. These elements are propelling FUE's popularity and ensuring its continuing expansion as a hair restoration procedure.

For many years, FUT has been a popular hair restoration method, and it remains a viable alternative for people seeking hair restoration. FUT is a well-established hair restoration procedure that is anticipated to flourish and grow in popularity in the next years, especially as technology advances and people become more aware of their alternatives. However, it is critical to select a trained and experienced practitioner for any hair restoration surgery, as the outcomes might vary widely depending on the practitioner's abilities and knowledge.

The Growing Number of Persons Experiencing Hair Loss will have an Impact on Regional Growth

North America, Europe, and Asia Pacific are among the most populous and fastest-growing markets for hair transplant treatments, owing to reasons such as ageing populations, rising disposable incomes, and increased knowledge of the process. Hair transplant market growth is being driven by an increase in the number of operations performed in the United States. According to the American Society of Plastic Surgery (ASPS), 24,348 hair transplantation surgeries were conducted in the United States in 2019.

Furthermore, a growth in physical appearance awareness among Europeans, as well as an increase in the number of people suffering from baldness, increases the need for hair transplant procedures. According to the New Look Institute, a hair restoration facility, in 2021, around 39.24% of the male population in France will be bald.

Emerging Asian countries are focusing on the development of superior healthcare facilities while reducing prices and medical tourism. Istanbul has become the Global Hair Transplant Capital. Turkish health institutions and physicians specialized in this topic have become a global phenomenon in recent years.

During the Projection Period, Platelet Rich Plasma Treatment is Predicted to Increase at a Faster CAGR

The market is divided into three segments based on therapy: low level laser therapy, stem cell hair restoration, and platelet rich plasma. Platelet-rich plasma therapy techniques in hair loss treatment are rapidly expanding, which is projected to enhance demand for platelet-rich plasma (PRP) therapy. Due to its non-surgical and minimally invasive nature, Platelet Rich Plasma (PRP) therapy for hair loss has grown in popularity in recent years. Rising popularity and efficacy of PRP therapy is projected to recover with minimum scarring following transplantation, leading in increased demand for platelet-rich plasma therapy throughout the projection period.

Stem cell hair restoration treatment is a novel and rapidly developing topic in the hair transplant business. Despite these emerging trends, stem cell hair restoration therapy is still in its infancy, and more study is required to properly understand its efficacy and long-term effects. Furthermore, not all clinics offering stem cell hair restoration therapy have the requisite experience and technology, so selecting a recognised and competent facility for treatment is critical.

Drug Product holds Majority of the Market Share

The hair transplant market is divided into gel, serum, medicines, multivitamins, and others based on product. The medication hair transplant market is continually growing, with new products and treatments being created on a regular basis. Minoxidil and finasteride are two regularly used drugs for the treatment of hair loss. Minoxidil is a topical drug that is readily accessible without a prescription and is used to treat both male and female pattern baldness. Finasteride is an oral medicine that is mostly used to treat male pattern baldness. It is taken on a daily basis and has been proved to be useful in certain men in reducing or preventing hair loss and encouraging hair growth.

Procedure - Hair Transplant Market breakup from 2 viewpoints:

1. Follicular Unit Extraction (FUE)2. Follicular Unit Transplantation (FUT)

Therapy - Hair Transplant Market breakup from 3 viewpoints:

1. Platelet Rich Plasma2. Stem Cell Therapy3. Laser Therapy

Product - Hair Transplant Market breakup from 5 viewpoints:

1. Gel2. Serum3. Hair Transplant4. Multivitamins5. Others

Region - Hair Transplant Market breakup from 5 viewpoints:

1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East & Africa

Service Provider - Hair Transplant Market breakup from 4 viewpoints:

1. Clinics2. Surgical Centers3. Hospitals4. Others

Story continues

Report Attribute

Details

No. of Pages

130

Forecast Period

2022 - 2028

Estimated Market Value (USD) in 2022

$14.74 Billion

Forecasted Market Value (USD) by 2028

$53.17 Billion

Compound Annual Growth Rate

23.8%

Regions Covered

Global

Companies Mentioned

Venus Concept Inc

Sisram Medical Ltd

CUTERA, INC

Allergan Plc

For more information about this report visit https://www.researchandmarkets.com/r/bex3hs-transplant?w=12

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

Link:
Hair Transplant Global Market Report 2023: Increasing use of Follicular Unit Extraction Drives Growth - Yahoo Finance

Guidelines International Society for Stem Cell Research

Academy of Medical Sciences (2011). Animals containing human material. http://www.acmedsci.ac.uk/policy/policy-projects/animals-containing-human-material/

American College of Obstetricians and Gynecologists (2006). Using preimplantation embryos for research. ACOG Committee Opinion No. 347. Obstet. Gynecol. 108, 13051317.

Bacman, S., Williams, S., Pinto, M. et al. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat Med 19, 11111113 (2013). https://doi.org/10.1038/nm.3261

Bacman SR, Kauppila JHK, Pereira CV, et al. MitoTALEN reduces mutant mtDNA load and restores tRNAAla levels in a mouse model of heteroplasmic mtDNA mutation [published correction appears in Nat Med. 2018 Oct 5;:]. Nat Med. 2018;24(11):16961700. doi:10.1038/s41591-018-0166-8

Benjaminy S, Kowal SP, MacDonald IM, Bubela T. Communicating the promise for ocular gene therapies: challenges and recommendations. Am J Ophthalmol. 2015 Sep;160(3):408-415.e2. doi: 10.1016/j.ajo.2015.05.026. Epub 2015 May 30. PMID: 26032192.

Boer, G. J. (1994). Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. Journal of Neurology 242, 113.

Boutron, I., Dutton, S., Ravaud, P., and Altman, D.G. (2010). Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303, 2058-2064.

Bubela T, McCabe C, Archibald P, Atkins H, Bradshaw SE, Kefalas P, Mujoomdar M, Packer C, Piret J, Raxworthy M, Soares M, Viswanathan S. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regen Med. 2015;10(7):897-911. doi: 10.2217/rme.15.51. Epub 2015 Nov 13. PMID: 26565607.

Camacho, L.H., Bacik, J., Cheung, A., and Spriggs, D.R. (2005). Presentation and subsequent publication rates of phase I oncology clinical trials. Cancer 104, 1497-1504.

Costa-Borges, N., Nikitos, E., Spath, K. et al. (2020) First registered pilot trial to validate the safety and effectiveness of maternal spindle transfer to overcome infertility associated with poor oocyte quality. Fertility & Sterility (Abstract only) 114, issue 3, supplement , e71-e72 https://doi.org/10.1016/j.fertnstert.2020.08.220

Council for International Organizations of Medical Sciences (2016). International Ethical Guidelines for Health-related Research Involving Humans. https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf

Department of Health, and Education and Welfare (1979). Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (The Belmont Report). 44 Fed. Reg. 23, 192.

ESHRE Taskforce on Ethics and Law (2001). The moral status of the pre-implantation embryo. Hum. Reprod. 17, 1409-1419.

Easson EC, Russell MH. Cure of Hodgkins disease. BMJ. 1963;5347:17047.

Ethics Committee of American Society for Reproductive Medicine (2013). Donating embryos for human embryonic stem cell (hESC) research: a committee opinion. Fertil. Steril. 100, 935-939.

European Parliament and Council of the European Union (2001). Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. (Official Journal of the European Union).

European Science Foundation (2000). Good scientific practice in research and scholarship. Science Policy Briefing. http://www.esf.org/fileadmin/Public_documents/Publications/ESPB10.pdf

Fisher, M., Feuerstein, G., Howells, D.W., Hurn, P.D., Kent, T.A., Savitz, S.I., and Lo, E.H. (2009). Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40, 2244-2250.

Flory, J., and Emanuel, E. (2004). Interventions to improve research participants' understanding in informed consent for research: a systematic review. JAMA 292, 1593-1601.

Food and Drug Administration (2017). FDA Announces Comprehensive Regenerative Medicine Policy Framework. https://www.fda.gov/news-events/press-announcements/fda-announces-comprehensive-regenerative-medicine-policy-framework

Freeman, G.A., and Kimmelman, J. (2012). Publication and reporting conduct for pharmacodynamic analyses of tumor tissue in early-phase oncology trials. Clinical Cancer Research 18, 6478-6484.

Frei, E. 3rd & Gehan, E. A. Definition of cure for Hodgkins disease. Cancer Res. 31, 18281833 (1971).

Fung M, Yuan Y, Atkins H, Shi Q, Bubela T. Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications. Stem Cell Reports. 2017 May 9;8(5):1190-1201. doi: 10.1016/j.stemcr.2017.03.013. Epub 2017 Apr 13. PMID: 28416287; PMCID: PMC5425617.

Haimes, E., Skene, L., Ballantyne, A.J., Caulfield, T., Goldstein, L.S., Hyun, I., Kimmelman, J., Robert, J.S., Roxland, B.E., Scott, C.T., et al. (2013). Position statement on the provision and procurement of human eggs for stem cell research. Cell Stem Cell 12, 285-291.

Henderson, V.C., Kimmelman, J., Fergusson, D., Grimshaw, J.M., and Hackam, D.G. (2013). Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Medicine 10, e1001489.

Hudson, G., Takeda, Y. & Herbert, M. Reversion after replacement of mitochondrial DNA. Nature 574, E8E11 (2019). https://doi.org/10.1038/s41586-019-1623-3

Human Fertilization and Embryology Authority (2016). Scientific review of the safety and efficacy of methods to avoid mitochondrial disease through assisted conception: 2016 update. https://www.hfea.gov.uk/media/2611/fourth_scientific_review_mitochondria_2016.pdf

Human Fertilization and Embryology Authority (2019). Code of Practice, 9th Edition. https://portal.hfea.gov.uk/media/1527/2019-12-16-code-of-practice-9th-edition-december-2019.pdf

Hyslop LA, Blakeley P, Craven L, Richardson J, Fogarty NM, Fragouli E, Lamb M, Wamaitha SE, Prathalingam N, Zhang Q, OKeefe H. Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. Nature. 2016 Jun 8 534: 383-386.

Hyun, I. (2013). Therapeutic hope, spiritual distress, and the problem of stem cell tourism. Cell Stem Cell12, 505-507.

Hyun, I., Taylor, P., Testa, G., Dickens, B., Jung, K. W., McNab, A., Roberston, J., Skene, L., and Zoloth, L. (2007). Ethical standards for human-to-animal chimera experiments in stem cell research. Cell Stem Cell 1, 159163.

International Society for Stem Cell Research (ISSCR). (2006). Guidelines for the conduct of human embryonic stem cell research. http://www.isscr.org/docs/default-source/hesc-guidelines/isscrhescguidelines2006.pdf.

International Society for Stem Cell Research (ISSCR). (2008). Guidelines for the clinical translation of stem cells. http://www.isscr.org/docs/default-source/clin-trans-guidelines/isscrglclinicaltrans.pdf.

International Society for Stem Cell Research (ISSCR). (2016). Guidelines for Stem Cell Research and Clinical Translation. https://www.isscr.org/docs/default-source/all-isscr-guidelines/guidelines-2016/isscr-guidelines-for-stem-cell-research-and-clinical-translationd67119731dff6ddbb37cff0000940c19.pdf?sfvrsn=4

Madan K. Natural human chimeras: A review. Eur J Med Genet. 2020 Sep;63(9):103971. doi: 10.1016/j.ejmg.2020.103971. Epub 2020 Jun 18. PMID: 32565253.

National Academy of Sciences, National Academy of Engineering, and Institute of Medicine. 2009. On Being a Scientist: A Guide to Responsible Conduct in Research: Third Edition. Washington, DC: The National Academies Press. https://doi.org/10.17226/12192.

National Academy of Medicine, National Academy of Sciences, and the Royal Society. 2020. Heritable Human Genome Editing. Washington, DC.: The National Academies Press. doi: 10.17226/25665.

Institute of Medicine (2015). Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risks (Washington, DC: National Academies Press). doi:10.17226/18998.

Nuffield Council on Bioethics. 2016. Genome Editing: An Ethical Review. https://www.nuffieldbioethics.org/wp-content/uploads/Genome-editing-an-ethical-review.pdf

Institute of Medicine and National Research Council. 2010. Final Report of the National Academies' Human Embryonic Stem Cell Research Advisory Committee and 2010 Amendments to the National Academies' Guidelines for Human Embryonic Stem Cell Research. Washington, DC: The National Academies Press. https://doi.org/10.17226/12923.

Kamenova, K., and Caulfield, T. (2015). Stem cell hype: media portrayal of therapy translation. Science Translational Medicine 7, 278ps274.

Kang, E., Koski, A., Amato, P. et al. Reply to: Reversion after replacement of mitochondrial DNA. Nature 574, E12E13 (2019). https://doi.org/10.1038/s41586-019-1624-2

Kang E, Wu J, Gutierrez NM, Koski A, Tippner-Hedges R, Agaronyan K, Platero-Luengo A, Martinez-Redondo P, Ma H, Lee Y, Hayama T, Van Dyken C, Wang X, Luo S, Ahmed R, Li Y, Ji D, Kayali R, Cinnioglu C, Olson S, Jensen J, Battaglia D, Lee D, Wu D, Huang T, Wolf DP, Temiakov D, Izpisua Belmonte JC, Amato P, Mitalipov S. Mitochondrial replacement in human oocytes carrying pathogenic mitochondrial DNA mutations. Nature 2016 DOI: 10.1038/nature20592

Kilkenny C, Browne WJ, Cuthill IC, Emerson M, and Altman DG (2010). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Plos Biol 8, e1000412.

Kimmelman, J., Mogil, J.S., Dirnagl, U. (2014). Distinguishing between Exploratory and Confirmatory Preclinical Research Will Improve Translation. PLoS Biol. 12, e1001863.

Kuriyan AE, Albini TA, Townsend JH, et al. Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD. N Engl J Med. 2017; 376(11):10471053. doi:10.1056/NEJMoa1609583

Landis, S.C., Amara, S.G., Asadullah, K., Austin, C.P., Blumenstein, R., Bradley, E.W., Crystal, R.G., Darnell, R.B., Ferrante, R.J., Fillit, H., et al. (2012). A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490, 187-191.

Lau, D., Ogbogu, U., Taylor, B., Stafinski, T., Menon, D., and Caulfield, T. (2008). Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 3, 591-594.

Mazur, P et al. 2019 P-221 Mitochondrial Replacement Therapy Gives No Benefits to Patients of Advanced Maternal Age. Paper presented to ASRM Scientific Conference and Expo, Philadelphia, Oct. 14-16. https://asrm.confex.com/asrm/2019/meetingapp.cgi/Paper/2347

Medical Professionalism Project (2002). Medical professionalism in the new millennium: a physician charter. Annals of Internal medicine 136, 243-246.

Munsie, M., and Hyun, I. (2014). A question of ethics: selling autologous stem cell therapies flaunts professional standards. Stem Cell Research 13, 647-653.

National Academies of Sciences, Engineering, and Medicine (2016). Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations. (Washington, DC: The National Academies Press). doi:10.17226/21871.

National Institutes of Health (2014). Informed Consent Guidance for Human Gene Trials subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (Office of Science Policy: Office of Biotechnology Activities). http://osp.od.nih.gov/sites/default/files/resources/IC2013.pdf

Nissanka N, Moraes CT. Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches. EMBO Rep. 2020;21(3):e49612. doi:10.15252/embr.201949612

Nuremberg Code (1949). In Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No 10, Vol 2 (Washington, DC: U.S. Government Printing Office), pp 181-182.

Office for Human Research Protections (OHRP) (1993). Research on Transplantation of Fetal Tissue SEC. 498A, National Institutes of Health Revitalization Act of 1993. http://www.hhs.gov/ohrp/policy/publiclaw103-43.htm.html

Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. (2020) The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol 18(7): e3000410. https://doi.org/10.1371/journal.pbio.3000410

Ravi, P., Kumar, S.K., Cerhan, J.R. et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer Journal 8, 26 (2018). https://doi.org/10.1038/s41408-018-0065-8:

Reddy, Pradeep et al. Selective Elimination of Mitochondrial Mutations in the Germline by Genome Editing. Cell, Volume 161, Issue 3 (2015) pp. 459 469. https://doi.org/10.1016/j.cell.2015.03.051

Saini, P., Loke, Y.K., Gamble, C., Altman, D.G., Williamson, P.R., and Kirkham, J.J. (2014). Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ 349, g6501.

SB-180 Gene therapy kits: advisory notice and labels.(2019-2020). California State Legislature.

S.D. Tardif, K. Coleman, T.R. Hobbs, C. Lutz, IACUC Review of Nonhuman Primate Research, ILAR Journal 53, no. 2, 2013: DOI: 10.1093/ilar/ilt040.

Sena, E.S., van der Worp, H.B., Bath, P.M., Howells, D.W., and Macleod, M.R. (2010). Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 8, e1000344.

Sugarman J, Siegel A. How to determine whether existing human embryonic stem cell lines can be used ethically. Cell Stem Cell 2008; 3: 238-9. PMID: 18786411.

Sugarman J, Siegel AW. When embryonic stem cell lines fail to meet consent standards. Science 2008; 322: 379. PMID: 18927375.

Tsilidis, K.K., Panagiotou, O.A., Sena, E.S., Aretouli, E., Evangelou, E., Howells, D.W., Al-Shahi Salman. R., Macleod, M.R., Ioannidis, J.P. (2013). Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol. 11, e1001609.

U.K. Department of Health (2014). Mitochondrial donation. Government response to the consultation on draft regulations to permit the use of new treatment techniques to prevent the transmission of a serious mitochondrial disease from mother to child. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/332881/Consultation_response.pdf

Wang, Tian et al. Polar Body Genome Transfer for Preventing the Transmission of Inherited Mitochondrial Diseases. Cell, 157 (2014), pp. 1591-1604. https://doi.org/10.1016/j.cell.2014.04.042

World Medical Association (2018). Declaration of Helsinki: Ethical principles for medical research involving human subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

Wu, K., Zhong, C., Chen, T. et al. Polar bodies are efficient donors for reconstruction of human embryos for potential mitochondrial replacement therapy. Cell Res 27, 10691072 (2017). https://doi.org/10.1038/cr.2017.67

Yamada M, Emmanuele V, Sanchez-Quintero MJ, Sun B, Lallos G, Paull D, Zimmer M, Pagett S, Prosser RW, Sauer MV, Hirano M. Genetic Drift Can Compromise Mitochondrial Replacement by Nuclear Transfer in Human Oocytes. Cell stem cell. 2016 Jun 2;18(6):749-54.

Zhang, John et al. Pregnancy derived from human zygote pronuclear transfer in a patient who had arrested embryos after IVF. Reproductive biomedicine online vol. 33,4 (2016): 529-533. doi:10.1016/j.rbmo.2016.07.008

Read more:
Guidelines International Society for Stem Cell Research